93 related articles for article (PubMed ID: 22771509)
1. Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults.
Bertolini DV; Costa LS; van der Heijden IM; Sato HK; Marques HH
Vaccine; 2012 Aug; 30(37):5482-6. PubMed ID: 22771509
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults.
de Voer RM; van der Klis FR; Engels CW; Schepp RM; van de Kassteele J; Sanders EA; Rijkers GT; Berbers GA
Vaccine; 2009 Nov; 27(50):6974-82. PubMed ID: 19800445
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.
Lee CH; Kuo WC; Beri S; Kapre S; Joshi JS; Bouveret N; LaForce FM; Frasch CE
Vaccine; 2009 Jan; 27(5):726-32. PubMed ID: 19063929
[TBL] [Abstract][Full Text] [Related]
4. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
[TBL] [Abstract][Full Text] [Related]
5. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
Keiser PB; Gibbs BT; Coster TS; Moran EE; Stoddard MB; Labrie JE; Schmiel DH; Pinto V; Chen P; Zollinger WD
Vaccine; 2010 Oct; 28(43):6970-6. PubMed ID: 20732470
[TBL] [Abstract][Full Text] [Related]
8. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
9. Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students.
Holmes JD; Martin D; Ramsay C; Ypma E; Oster P
Epidemiol Infect; 2008 Jun; 136(6):790-9. PubMed ID: 17678558
[TBL] [Abstract][Full Text] [Related]
10. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of conjugate meningococcus C vaccine in pediatric solid organ transplant recipients.
Zlamy M; Elias J; Vogel U; Frosch M; Jeller V; Cortina G; Jungraithmayr T; Prelog M
Vaccine; 2011 Aug; 29(37):6163-6. PubMed ID: 21718742
[TBL] [Abstract][Full Text] [Related]
12. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
13. Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants.
Schmitt HJ; Steul KS; Borkowski A; Ceddia F; Ypma E; Knuf M
Vaccine; 2008 Apr; 26(18):2242-52. PubMed ID: 18407386
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
[TBL] [Abstract][Full Text] [Related]
16. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
17. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.
McVernon J; MacLennan J; Pollard AJ; Oster P; Wakefield MJ; Danzig L; Moxon ER
Pediatr Infect Dis J; 2003 Jul; 22(7):659-61. PubMed ID: 12886896
[TBL] [Abstract][Full Text] [Related]
18. Prevention of meningococcal serogroup C disease by NeisVac-C.
Borrow R; Findlow J
Expert Rev Vaccines; 2009 Mar; 8(3):265-79. PubMed ID: 19249967
[TBL] [Abstract][Full Text] [Related]
19. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
